Results 271 to 280 of about 767,219 (291)

Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications. [PDF]

Front Immunol
Zhao L, Li X, Jing Y, Tang L, Lin F, Zhang Y, Tang Y, Chen C, Yang J, Liu X, Chen J.   +10 more
europepmc   +1 more source

Sanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma

Advanced Science, EarlyView.
Sanggenol L, a flavonoid from mulberry, enhances glioblastoma sensitivity to temozolomide by inhibiting mitophagy and inducing apoptosis through TRIM16‐mediated OPTN degradation. In animal studies, liposomal delivery of Sanggenol L significantly improves the efficacy of its combination with TMZ, providing new insights into glioblastoma treatment ...
Hongbo Chang, Jianbing Hou, Xin Hu, Nana Hou, Minghao Xu, Yi Du, Jingyang Xu, Yongzhao Wang, Zhuohao Xie, Junbo Shi, Yundong Zhang, Hongjuan Cui   +11 more
wiley   +1 more source

Therapeutic Intensification Based on Immune Checkpoint Inhibitors in Non-Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives. [PDF]

Cancers (Basel)
Gabriel PE, Horowitz A, Guerrero-Ramos F, Soria F, Moschini M, D'Andrea D, Pradère B, Sfakianos JP, Xylinas E.   +8 more
europepmc   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

Advanced Science, EarlyView.
IDH‐mutant gliomas exhibit sensitivity to PARP inhibitors (PARPi) owing to oncometabolite 2‐HG‐induced DNA repair defects. PARPi treatment induces resistance by upregulating Prickle4, which promotes VEGF‐driven angiogenesis. Combining PARPi veliparib with anti‐angiogenic lenvatinib blocks this pathway, causing tumor regression and prolonged survival in
Ju Yang, Hua Yang, Yifan Yuan, Chenyang Zhang, Ziwei Fu, Yanyan Chen, Yinghong Xiong, Shuyu Chen, Kexin Ling, Ying Liu, Jason T. Huse, Bo Chen, Timothy A. Chan, Zengxin Qi, Zhao Zhang, Xiuping Liu, Yuxiang Wang   +16 more
wiley   +1 more source

Immunotherapy research for prostate cancer from 2000 to 2024: a bibliometric and visualization analysis. [PDF]

Transl Androl Urol
Li B, Wu T, Dong M, Ye K, Wang J, Ren C.
europepmc   +1 more source

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

Advanced Science, EarlyView.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu   +15 more
wiley   +1 more source

Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers. [PDF]

Clin Exp Med
Pirouzbakht M, Hamzeh S, Soleimani Samarkhazan H.   +2 more
europepmc   +1 more source

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Advanced Science, EarlyView.
Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan   +4 more
wiley   +1 more source